Intervention in Patients with Takayasu Arteritis: Rescue Therapy or an Alternative Complementary to Immunosuppressive Therapy?

Takayasu arteritis (TAK) is an uncommon granulomatous large-vessel vasculitis that affects the aorta and its primary branches. The most frequently types of observed vascular compromise are obstructive lesions, and aneurysmal vascular lesions or dissections. In 2021, the American College of Rheumatology recommended not to implement percutaneous intervention (PI) with these patients and only use immunosuppressive<a href="https://solaci.org/en/2023/01/18/intervention-in-patients-with-takayasu-arteritis-rescue-therapy-or-an-alternative-complementary-to-immunosuppressive-therapy/" title="Read more" >...</a>

ESC 2022 | Should We Follow-Up with Functional Testing in High-Risk Patients after CTA?

While the need for repeat cinecoronary angiography after transluminal coronary angioplasty (TCA) has decreased with the use of drug-eluting stents and improved medical treatment, patients still present ischemic recurrence or cardiovascular events at follow-up. Using a functional test at follow-up after TCA or myocardial revascularization (CMR) is a frequent practice in our context. This is<a href="https://solaci.org/en/2022/09/05/esc-2022-should-we-follow-up-with-functional-testing-in-high-risk-patients-after-cta/" title="Read more" >...</a>

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise.<a href="https://solaci.org/en/2022/06/01/revascularization-using-des-in-infrapopliteal-disease-meta-analysis-and-change-of-paradigm/" title="Read more" >...</a>

AHA 2021 | Meta-análisis de cirugía vs angioplastia para el tronco de la coronaria izquierda

AHA 2021 | Meta-Analysis of Surgery vs. Angioplasty in Left Main Coronary Artery Disease

According to this new meta-analysis (presented at AHA 2021 and published in The Lancet), mortality is similar between surgery and angioplasty to treat left main coronary artery in patients with simple or intermediate anatomy. This new study estimates that, after 5 years, mortality with surgery would be 11.2% vs. 10.2% with angioplasty, a non-significant difference. This debate<a href="https://solaci.org/en/2021/11/25/aha-2021-meta-analysis-of-surgery-vs-angioplasty-in-left-main-coronary-artery-disease/" title="Read more" >...</a>

The Most Read Articles in Interventional Cardiology of October

The Most Read Articles in Interventional Cardiology in October

01- ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Read also HERE 02- Chile Sessions 2021 | Clinical Case Contest for Young Interventionists It is with great<a href="https://solaci.org/en/2021/11/05/the-most-read-articles-in-interventional-cardiology-in-october/" title="Read more" >...</a>

The Most Read Articles in August in Interventional Cardiology

01- Best Revascularization Strategy in Patients with Left Ventricular Deterioration Multivessel disease associated to ventricular function deterioration is challenging in terms of risk, when choosing a revascularization strategy.  Read also HERE 02- SOLACI Renewed Authorities During the SOLACI-CACI 2021 Congress After a massive event attended by thousands of people, the Latin American Society of Interventional Cardiology renewed its authorities for<a href="https://solaci.org/en/2021/09/10/the-most-read-articles-in-august-in-interventional-cardiology/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES. The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs<a href="https://solaci.org/en/2021/08/13/the-long-marathon-of-ultrathin-vs-2nd-generation-thin-strut-des/" title="Read more" >...</a>

Novel DES Technology Promises to Become the Next DES Generation

The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Accelerated endothelial healing after antiproliferative drug release may limit the long-term inflammatory response. This multicenter, single-blind study included 1600 patients who were randomized 2:1 to receive drug-eluting stent Supreme vs. a classic permanent-polymer everolimus-eluting<a href="https://solaci.org/en/2021/07/13/novel-des-technology-promises-to-become-the-next-des-generation/" title="Read more" >...</a>

The Most Read Articles on Interventional Cardiology of March

The Most Read Articles in Interventional Cardiology of March

01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. Read more HERE 02- Major Cause of Myocardial Injury by COVID-19 The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These<a href="https://solaci.org/en/2021/04/07/the-most-read-articles-in-interventional-cardiology-of-march/" title="Read more" >...</a>

DES con polímero bioabsorbible vs Bare Metal Stents en angioplastia primaria

Biodegradable Polymer Myth Also Debunked for ACSs

During TCT 2020 a preview of the results of the comparison of drug-eluting stents (DES) with biodegradable-polymer vs. durable-polymer in patients with acute coronary syndrome (ACS) was presented. The fine print and the final paper for HOST-REDUCE-POLYTECH-ACS are now published, and they lower the expectations set on biodegradable polymers. In patients with ACS undergoing angioplasty, biodegradable-polymer<a href="https://solaci.org/en/2021/04/05/biodegradable-polymer-myth-also-debunked-for-acss/" title="Read more" >...</a>